FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL							
l	OMB Number:	3235-0287						
l	Estimated average burde	en						
l	hours per response:	0.5						

	Check this box if no longer subject to							
$\neg$	Section 16. Form 4 or Form 5							
J	obligations may continue. See							
	Instruction 1(b).							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					i occii	011 30(11) (	JI LITE	investment C	ompany Act	01 1340							
1. Name and Address of Reporting Person* <u>Landis John B.</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol  EyePoint Pharmaceuticals, Inc. [ EYPT ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET				10	3. Date of Earliest Transaction (Month/Day/Year) 10/25/2018								(give title		Other (s below)		
(Street) WATERTOWN MA 02472 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
		Tab	le I - Non-D	Perivativ	e Se	curities	s Ac	quired, Di	sposed o	of, or Be	neficial	y Owned					
1. Title of Security (Instr. 3) 2. Transac Date				Transactio ate Ionth/Day/Y	2A. Deemed Execution Date,		Code (Ins	on Disposed tr. 5)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3,		5. Amount of Securities Beneficially		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		-	Table II - De (e.					uired, Dis s, options,				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Ownersh Form: y Direct (D or Indire (I) (Instr.	Ownership	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$2.27	10/25/2018		A		80,000		(1)	10/25/2028	Common Stock	80,000	\$0.00	80,000		D		

## **Explanation of Responses:**

1. The option becomes exercisable in three equal annual installments beginning on October 25, 2019.

## Remarks:

/s/ John Mercer, Attorney-in-

\*\* Signature of Reporting Person

Date

10/29/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.